Androgen receptor antagonism by divalent ethisterone conjugates in castrate-resistant prostate cancer cells

Paul M. Levine, Eugine Lee, Alex Greenfield, Richard Bonneau, Susan K. Logan, Michael J. Garabedian, Kent Kirshenbaum

Research output: Contribution to journalArticle

Abstract

Sustained treatment of prostate cancer with androgen receptor (AR) antagonists can evoke drug resistance, leading to castrate-resistant disease. Elevated activity of the AR is often associated with this highly aggressive disease state. Therefore, new therapeutic regimens that target and modulate AR activity could prove beneficial. We previously introduced a versatile chemical platform to generate competitive and non-competitive multivalent peptoid oligomer conjugates that modulate AR activity. In particular, we identified a linear and a cyclic divalent ethisterone conjugate that exhibit potent anti-proliferative properties in LNCaP-abl cells, a model of castrate-resistant prostate cancer. Here, we characterize the mechanism of action of these compounds utilizing confocal microscopy, time-resolved fluorescence resonance energy transfer, chromatin immunoprecipitation, flow cytometry, and microarray analysis. The linear conjugate competitively blocks AR action by inhibiting DNA binding. In addition, the linear conjugate does not promote AR nuclear localization or co-activator binding. In contrast, the cyclic conjugate promotes AR nuclear localization and induces cell-cycle arrest, despite its inability to compete against endogenous ligand for binding to AR in vitro. Genome-wide expression analysis reveals that gene transcripts are differentially affected by treatment with the linear or cyclic conjugate. Although the divalent ethisterone conjugates share extensive chemical similarities, we illustrate that they can antagonize the AR via distinct mechanisms of action, establishing new therapeutic strategies for potential applications in AR pharmacology.

Original languageEnglish (US)
Pages (from-to)1693-1701
Number of pages9
JournalACS Chemical Biology
Volume7
Issue number10
DOIs
StatePublished - Oct 19 2012

Fingerprint

Ethisterone
Androgen Receptors
Prostatic Neoplasms
Cells
Peptoids
Genes
Androgen Receptor Antagonists
Fluorescence Resonance Energy Transfer
Flow cytometry
Confocal microscopy
Chromatin Immunoprecipitation
Microarray Analysis
Microarrays
Cell Cycle Checkpoints
Oligomers
Drug Resistance
Confocal Microscopy
Chromatin
Flow Cytometry

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Medicine(all)

Cite this

Androgen receptor antagonism by divalent ethisterone conjugates in castrate-resistant prostate cancer cells. / Levine, Paul M.; Lee, Eugine; Greenfield, Alex; Bonneau, Richard; Logan, Susan K.; Garabedian, Michael J.; Kirshenbaum, Kent.

In: ACS Chemical Biology, Vol. 7, No. 10, 19.10.2012, p. 1693-1701.

Research output: Contribution to journalArticle

Levine, Paul M. ; Lee, Eugine ; Greenfield, Alex ; Bonneau, Richard ; Logan, Susan K. ; Garabedian, Michael J. ; Kirshenbaum, Kent. / Androgen receptor antagonism by divalent ethisterone conjugates in castrate-resistant prostate cancer cells. In: ACS Chemical Biology. 2012 ; Vol. 7, No. 10. pp. 1693-1701.
@article{8708ab210ca642f5a55ee9dad56b8a3d,
title = "Androgen receptor antagonism by divalent ethisterone conjugates in castrate-resistant prostate cancer cells",
abstract = "Sustained treatment of prostate cancer with androgen receptor (AR) antagonists can evoke drug resistance, leading to castrate-resistant disease. Elevated activity of the AR is often associated with this highly aggressive disease state. Therefore, new therapeutic regimens that target and modulate AR activity could prove beneficial. We previously introduced a versatile chemical platform to generate competitive and non-competitive multivalent peptoid oligomer conjugates that modulate AR activity. In particular, we identified a linear and a cyclic divalent ethisterone conjugate that exhibit potent anti-proliferative properties in LNCaP-abl cells, a model of castrate-resistant prostate cancer. Here, we characterize the mechanism of action of these compounds utilizing confocal microscopy, time-resolved fluorescence resonance energy transfer, chromatin immunoprecipitation, flow cytometry, and microarray analysis. The linear conjugate competitively blocks AR action by inhibiting DNA binding. In addition, the linear conjugate does not promote AR nuclear localization or co-activator binding. In contrast, the cyclic conjugate promotes AR nuclear localization and induces cell-cycle arrest, despite its inability to compete against endogenous ligand for binding to AR in vitro. Genome-wide expression analysis reveals that gene transcripts are differentially affected by treatment with the linear or cyclic conjugate. Although the divalent ethisterone conjugates share extensive chemical similarities, we illustrate that they can antagonize the AR via distinct mechanisms of action, establishing new therapeutic strategies for potential applications in AR pharmacology.",
author = "Levine, {Paul M.} and Eugine Lee and Alex Greenfield and Richard Bonneau and Logan, {Susan K.} and Garabedian, {Michael J.} and Kent Kirshenbaum",
year = "2012",
month = "10",
day = "19",
doi = "10.1021/cb300332w",
language = "English (US)",
volume = "7",
pages = "1693--1701",
journal = "ACS Chemical Biology",
issn = "1554-8929",
publisher = "American Chemical Society",
number = "10",

}

TY - JOUR

T1 - Androgen receptor antagonism by divalent ethisterone conjugates in castrate-resistant prostate cancer cells

AU - Levine, Paul M.

AU - Lee, Eugine

AU - Greenfield, Alex

AU - Bonneau, Richard

AU - Logan, Susan K.

AU - Garabedian, Michael J.

AU - Kirshenbaum, Kent

PY - 2012/10/19

Y1 - 2012/10/19

N2 - Sustained treatment of prostate cancer with androgen receptor (AR) antagonists can evoke drug resistance, leading to castrate-resistant disease. Elevated activity of the AR is often associated with this highly aggressive disease state. Therefore, new therapeutic regimens that target and modulate AR activity could prove beneficial. We previously introduced a versatile chemical platform to generate competitive and non-competitive multivalent peptoid oligomer conjugates that modulate AR activity. In particular, we identified a linear and a cyclic divalent ethisterone conjugate that exhibit potent anti-proliferative properties in LNCaP-abl cells, a model of castrate-resistant prostate cancer. Here, we characterize the mechanism of action of these compounds utilizing confocal microscopy, time-resolved fluorescence resonance energy transfer, chromatin immunoprecipitation, flow cytometry, and microarray analysis. The linear conjugate competitively blocks AR action by inhibiting DNA binding. In addition, the linear conjugate does not promote AR nuclear localization or co-activator binding. In contrast, the cyclic conjugate promotes AR nuclear localization and induces cell-cycle arrest, despite its inability to compete against endogenous ligand for binding to AR in vitro. Genome-wide expression analysis reveals that gene transcripts are differentially affected by treatment with the linear or cyclic conjugate. Although the divalent ethisterone conjugates share extensive chemical similarities, we illustrate that they can antagonize the AR via distinct mechanisms of action, establishing new therapeutic strategies for potential applications in AR pharmacology.

AB - Sustained treatment of prostate cancer with androgen receptor (AR) antagonists can evoke drug resistance, leading to castrate-resistant disease. Elevated activity of the AR is often associated with this highly aggressive disease state. Therefore, new therapeutic regimens that target and modulate AR activity could prove beneficial. We previously introduced a versatile chemical platform to generate competitive and non-competitive multivalent peptoid oligomer conjugates that modulate AR activity. In particular, we identified a linear and a cyclic divalent ethisterone conjugate that exhibit potent anti-proliferative properties in LNCaP-abl cells, a model of castrate-resistant prostate cancer. Here, we characterize the mechanism of action of these compounds utilizing confocal microscopy, time-resolved fluorescence resonance energy transfer, chromatin immunoprecipitation, flow cytometry, and microarray analysis. The linear conjugate competitively blocks AR action by inhibiting DNA binding. In addition, the linear conjugate does not promote AR nuclear localization or co-activator binding. In contrast, the cyclic conjugate promotes AR nuclear localization and induces cell-cycle arrest, despite its inability to compete against endogenous ligand for binding to AR in vitro. Genome-wide expression analysis reveals that gene transcripts are differentially affected by treatment with the linear or cyclic conjugate. Although the divalent ethisterone conjugates share extensive chemical similarities, we illustrate that they can antagonize the AR via distinct mechanisms of action, establishing new therapeutic strategies for potential applications in AR pharmacology.

UR - http://www.scopus.com/inward/record.url?scp=84867786721&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867786721&partnerID=8YFLogxK

U2 - 10.1021/cb300332w

DO - 10.1021/cb300332w

M3 - Article

C2 - 22871957

AN - SCOPUS:84867786721

VL - 7

SP - 1693

EP - 1701

JO - ACS Chemical Biology

JF - ACS Chemical Biology

SN - 1554-8929

IS - 10

ER -